Bo Lak Net Assets
Bo Lak net assets. Based on the latest financial reports, Bo Lak (002760) has net assets worth ₩49.68 Billion KRW (≈ $33.67 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩58.45 Billion ≈ $39.61 Million USD) and total liabilities (₩8.77 Billion ≈ $5.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 002760 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩49.68 Billion |
| % of Total Assets | 85.0% |
| Annual Growth Rate | 1.82% |
| 5-Year Change | 7.0% |
| 10-Year Change | 13.99% |
| Growth Volatility | 3.28 |
Net Assets of Bo Lak (2013–2025)
Net assets of Bo Lak from 2013 to 2025. This chart illustrates how Bo Lak's net assets have evolved over time, based on quarterly financial data. See Bo Lak balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Bo Lak (2013–2025)
The table below shows the annual net assets of Bo Lak from 2013 to 2025. For live market cap and overall valuation, see Bo Lak stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩48.73 Billion ≈ $33.02 Million |
+4.46% |
| 2024-12-31 | ₩46.65 Billion ≈ $31.61 Million |
-4.36% |
| 2023-12-31 | ₩48.78 Billion ≈ $33.06 Million |
+0.82% |
| 2022-12-31 | ₩48.38 Billion ≈ $32.79 Million |
+6.24% |
| 2021-12-31 | ₩45.54 Billion ≈ $30.86 Million |
+3.50% |
| 2020-12-31 | ₩44.00 Billion ≈ $29.82 Million |
+0.13% |
| 2019-12-31 | ₩43.95 Billion ≈ $29.78 Million |
+0.42% |
| 2018-12-31 | ₩43.76 Billion ≈ $29.66 Million |
+1.26% |
| 2017-12-31 | ₩43.22 Billion ≈ $29.29 Million |
+1.10% |
| 2016-12-31 | ₩42.75 Billion ≈ $28.97 Million |
+6.85% |
| 2015-12-31 | ₩40.01 Billion ≈ $27.11 Million |
-2.73% |
| 2014-12-31 | ₩41.13 Billion ≈ $27.88 Million |
+4.80% |
| 2013-12-31 | ₩39.25 Billion ≈ $26.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bo Lak's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 55.7% over the analyzed period, indicating profitable operations and earnings retention.
Bo Lak Net Assets Breakdown (December 2025)
Bo Lak net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩26.26 Billion | 53.89% |
| Other Components | ₩22.47 Billion | 46.11% |
| Total Equity | ₩48.73 Billion | 100.00% |
Bo Lak Competitors by Market Cap
The table below lists competitors of Bo Lak ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Able View Global Inc. Class B Ordinary Shares
NASDAQ:ABLV
|
$39.95 Million |
|
Elicio Therapeutics Inc.
NASDAQ:ELTX
|
$39.95 Million |
|
Electra Battery Materials Corp
V:ELBM
|
$39.97 Million |
|
IHQ Inc
KO:003560
|
$39.98 Million |
|
Cybertech Systems And Software Limited
NSE:CYBERTECH
|
$39.94 Million |
|
HAV GROUP ASA
F:6HH
|
$39.94 Million |
|
IRIS Corporation Bhd
KLSE:0010
|
$39.94 Million |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
$39.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bo Lak's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 46,650,925,480 to 48,730,562,780, a change of 2,079,637,300 (4.5%).
- Net income of 2,339,631,890 contributed positively to equity growth.
- Dividend payments of 299,500,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.34 Billion | +4.8% |
| Dividends Paid | ₩299.50 Million | -0.61% |
| Other Changes | ₩39.51 Million | +0.08% |
| Total Change | ₩- | 4.46% |
Book Value vs Market Value Analysis
This analysis compares Bo Lak's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.36x to 1.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩721.51 | ₩984.00 | x |
| 2018-12-31 | ₩730.57 | ₩984.00 | x |
| 2019-12-31 | ₩733.67 | ₩984.00 | x |
| 2020-12-31 | ₩734.59 | ₩984.00 | x |
| 2021-12-31 | ₩760.33 | ₩984.00 | x |
| 2022-12-31 | ₩807.74 | ₩984.00 | x |
| 2023-12-31 | ₩814.34 | ₩984.00 | x |
| 2024-12-31 | ₩778.81 | ₩984.00 | x |
| 2025-12-31 | ₩813.53 | ₩984.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bo Lak utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.67%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.22x
- Recent ROE (4.80%) is above the historical average (2.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 1.83% | 2.34% | 0.62x | 1.27x | ₩-3.21 Billion |
| 2014 | 5.06% | 6.68% | 0.60x | 1.25x | ₩-2.03 Billion |
| 2015 | -0.43% | -0.56% | 0.63x | 1.24x | ₩-4.17 Billion |
| 2016 | 7.09% | 8.49% | 0.67x | 1.24x | ₩-1.24 Billion |
| 2017 | 2.87% | 3.70% | 0.65x | 1.20x | ₩-3.08 Billion |
| 2018 | 2.53% | 3.27% | 0.63x | 1.22x | ₩-3.27 Billion |
| 2019 | 1.48% | 1.80% | 0.65x | 1.27x | ₩-3.75 Billion |
| 2020 | 0.90% | 1.03% | 0.71x | 1.23x | ₩-4.01 Billion |
| 2021 | 3.72% | 4.26% | 0.71x | 1.24x | ₩-2.86 Billion |
| 2022 | 6.34% | 6.34% | 0.80x | 1.26x | ₩-1.77 Billion |
| 2023 | 1.76% | 1.83% | 0.81x | 1.19x | ₩-4.02 Billion |
| 2024 | -3.24% | -3.17% | 0.80x | 1.27x | ₩-6.17 Billion |
| 2025 | 4.80% | 4.67% | 0.85x | 1.22x | ₩-2.53 Billion |
Industry Comparison
This section compares Bo Lak's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $1,411,102,117,724
- Average return on equity (ROE) among peers: 4.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bo Lak (002760) | ₩49.68 Billion | 1.83% | 0.18x | $39.94 Million |
| DL Holdings CO. LTD. (000210) | $5.15 Trillion | 5.16% | 1.41x | $565.25 Million |
| DL Holdings Co Ltd Preferred (000215) | $4.92 Trillion | -1.79% | 1.48x | $22.38 Million |
| Norooholdings (000320) | $660.83 Billion | 3.78% | 0.77x | $96.82 Million |
| Noroo Holdings Co Ltd (000325) | $533.52 Billion | 2.04% | 0.82x | $4.49 Million |
| Samhwa Paint (000390) | $111.40 Billion | 6.40% | 1.03x | $107.63 Million |
| Kangnam Jevisco Co Ltd (000860) | $678.85 Billion | 0.91% | 0.41x | $107.48 Million |
| Paik Kwang Ind (001340) | $120.49 Billion | 1.97% | 1.33x | $126.11 Million |
| Songwon Industrial (004430) | $378.13 Billion | 9.36% | 1.29x | $170.78 Million |
| Cho Kwang Pain (004910) | $150.26 Billion | 11.15% | 0.61x | $20.43 Million |
About Bo Lak
Bolak Company Limited engages in the manufacture and sale of food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in South Korea and internationally. The company offers confectionery, beverage, micron, and dairy flavoring products; active pharmaceutical ingredients, such as dry and soft extract powders, fluid extracts, tinctures, natural paclitaxel, docet… Read more